Takahiro Kamio

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial

Kensei Yamaguchi, Yung‐Jue Bang, Satoru Iwasa et al. · Journal of Clinical Oncology · 2022 · 105 citations · Full text

Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial

Kanwal Raghav, Salvatore Siena, Atsuo Takashima et al. · The Lancet Oncology · 2024 · 87 citations

Oncology, Gastrointestinal Oncology, Primary Results +7

Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.

Kanwal Raghav, Salvatore Siena, Atsuo Takashima et al. · Journal of Clinical Oncology · 2023 · 68 citations · Full text

Primary Results, Immunology, Immunoediting +23

R-Ras Regulates Exocytosis by Rgl2/Rlf-mediated Activation of RalA on Endosomes

Akiyuki Takaya, Takahiro Kamio, Michitaka Masuda et al. · Molecular Biology of the Cell · 2007 · 56 citations · Full text

R-ras Regulates Exocytosis, Regulates Exocytosis, Immunology +17